Register for our free email digests:
John Davis
Writer

Latest From John Davis
UCB And Microsoft Expand AI Tie-Up Beyond COVID-19
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
Italfarmaco's Givinostat Encouraging In DMD, But Awaiting 2022 Pivotal Study Results
Italy’s Italfarmaco expects top-line data from its pivotal Phase III study of givinostat in Duchenne muscular dystrophy in the middle of next year, as the HDAC inhibitor continues to accrue data from the extension of its Phase II study.
Pipeline Watch: Phase III Results In AMD, Type 2 Diabetes, Psoriasis
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Sobi Eyes International Expansion With Growing Late-Stage Pipeline
Sobi is extending its reach in international markets including Russia and China and expects its late-stage R&D pipeline to drive growth.
Basilea Looks To Progress Cancer Pipeline As It Expands Zevtera Use
Switzerland’s Basilea Pharmaceutica is progressing its lead oncology candidates and a second late-stage US clinical trial of ceftobiprole in difficult-to-treat infections.
Orion Pushing Ahead In Prostate Cancer, R&D Reorganized
Finland’s Orion Corporation is highlighting its prostate cancer and other oncology candidates in its reorganized R&D.